Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Boston Scientific Corporation (NYSE:BSX)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on July 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Boston Scientific stock on June 5th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Roadhouse (NASDAQ:TXRH) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Capital Bancshares (NASDAQ:TCBI) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Microchip Technology (NASDAQ:MCHP) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 6/30/2026.

Boston Scientific Trading Down 0.1%

BSX stock opened at $45.09 on Friday. The company has a market capitalization of $67.01 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 0.86 and a beta of 0.58. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50. The company’s 50 day moving average price is $50.99 and its two-hundred day moving average price is $69.43. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the business posted $0.75 EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Hedge funds have recently modified their holdings of the company. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the second quarter valued at about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth about $26,000. Bangor Savings Bank increased its holdings in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific during the 1st quarter valued at approximately $28,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on BSX. Royal Bank Of Canada reissued an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Robert W. Baird set a $70.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Weiss Ratings lowered Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Oppenheimer set a $90.00 price target on Boston Scientific in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $83.36.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.